Current Colorectal Cancer Reports

, 7:267

Prognostic and Predictive Markers in Colorectal Cancer

Translational Colorectal Oncology (Yixing Jiang, Section Editor)

DOI: 10.1007/s11888-011-0104-3

Cite this article as:
Reddy, S., Vergo, M. & Benson, A.B. Curr Colorectal Cancer Rep (2011) 7: 267. doi:10.1007/s11888-011-0104-3
  • 76 Downloads

Abstract

Prognostic and predictive biomarkers have revolutionized medicine by allowing individualized treatment decisions. Most notably in oncology, where treatment can be associated with significant toxicities and often unpredictable outcomes, there is a need to isolate patients that are likely to benefit from an intervention. In colorectal cancer, there are many markers being investigated but only a few that have sufficient evidence to warrant use in clinical practice. This paper will review these prominent biomarkers in both adjuvant and metastatic colorectal cancer and summarize the data regarding their utility. The markers reviewed include microsatellite instability, 18qLOH, gene profile assays such as ColoPrint and Oncotype DX, Kras, Braf, thymidylate synthase, and circulating tumor cells. The paper will also discuss optimal clinical trial design, with a focus on different validation strategies for emerging biomarkers. By highlighting the pertinent literature, the hope is to facilitate a personalized approach to colorectal cancer care.

Keywords

PrognosticPredictiveBiomarkersColorectalColonKrasBrafCirculating tumor cellsMicrosatellite instabilityMSI-HdMMRDeficient mismatch repair18qLOHThymidylate synthaseColoprintOncotype dxGene profilingClinical trial design

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Sangeetha Reddy
    • 1
  • Maxwell Vergo
    • 2
  • Al B. BensonIII
    • 2
  1. 1.Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  2. 2.Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer CenterNorthwestern UniversityChicagoUSA